The country’s trajectory has been building for years. A fast-growing middle-income population, rising chronic disease burden, and expanding health infrastructure have created both demand and urgency. What is changing now is the environment in which innovation can move, driving faster approvals, a culture of collaboration, digital infrastructure and a government signaling policy readiness to engage global partners in shaping the next era of medicine.

The economic momentum is significant. The Indian health ecosystem has expanded from roughly $372 billion in 2023 to $638 billion in 2025, making it one of the fastest-growing major health markets in the world. The broader industry is expected to exceed $610 billion by 2026, fueled by rising insurance coverage, expanding hospital infrastructure, and growing demand for chronic disease management. Health growth in India continues at approximately 10–12 percent annually, well above the growth rates typical of mature markets, reflecting both rising access and structural transformation.

BIOAsia 2026 reflects this inflection point. The global gathering in Hyderabad, themed “TechBio Unleashed: AI, Automation & the Biology Revolution,” highlights the (bio)convergence of biology, data, and intelligent systems reshaping health worldwide. Organizers emphasize that the meeting aims to drive health transformation and reinforce India’s position as a leading global life sciences force. For multinational innovators, the message is increasingly clear: India is not only where innovation is deployed; it is also where it is developed. It is where innovation is increasingly defined. India has become a go-to market for multinational enterprises.

Policy Signals and Market Scale: From Opportunity to Strategic Partnership

India’s regulatory and policy environment is evolving in ways that matter deeply to multinational innovators. One pivotal shift came with the country’s decision to allow certain medicines approved in specified developed markets to launch without local clinical trials, a move designed to accelerate patient access while aligning more closely with global regulatory science. This policy shift reflected confidence in international data, a commitment to innovation, and recognition that faster access must remain central to national health strategy.

The scale of India’s pharmaceutical and life sciences market reinforces this transformation. The pharmaceutical sector reached approximately $68 billion in 2025 and is projected to grow to more than $170 billion during the next decade, driven by expanding middle-income demand and strong domestic manufacturing. India already supplies roughly one-fifth of the world’s generic medicines. It produces the majority of global vaccines by volume, positioning the country as a central player in global health supply chains.

As Aman Gupta of SPAG/FINN wrote in Medika Life, “India’s health sector is undergoing a profound transformation, bolstered by government-led reforms and a favorable FDI regime. The allowance of 100% foreign direct investment through automatic routes in health and related sectors has already attracted global giants.” His observation reinforces a central reality for multinational innovators: India’s policy environment is increasingly designed not only to welcome global participation, but to encourage long-term strategic partnership in building the future of healthcare.

Investment trends tell the same story. Health and pharmaceutical private equity and venture investments have reached multi-billion-dollar levels annually. At the same time, India’s contract drug development and manufacturing sector is projected to exceed $22 billion within the next decade. These dynamics position India as a growth market and as a strategic partner across the innovation lifecycle from discovery and clinical development to manufacturing and global distribution.

Shakthi Nagappan, CEO of Telangana Life Sciences Foundation, captured this moment clearly, noting that BIOAsia arrives at a time when technology and biology are redefining healthcare and creating “unprecedented opportunities for innovation, investment, and impact.” The language reflects partnership rather than transaction, a signal that India is moving from market opportunity to strategic collaboration.

Digital Infrastructure, BIOAsia and the Multinational Innovation Imperative

India’s digital transformation may be its most potent catalyst for long-term health innovation. Unlike many mature systems, the country is building a national-scale digital health infrastructure designed to connect patients, providers, and health systems across a population of more than 1.4 billion people, with a rising middle class of 400 million.

The Global Digital Health Market is projected to grow from USD 288.55 billion in 2024 to USD 2,688 billion by 2035, expanding at a CAGR of 22.55% during 2025–2035. This surge is driven by the rapid adoption of AI-powered diagnostics, telemedicine, wearable devices, and data analytics solutions that are revolutionizing patient care and operational efficiency worldwide.

Hundreds of millions of citizens are already using digital health services, including telemedicine, electronic prescriptions, and remote care. The Ayushman Bharat Digital Mission is creating an interoperable national health ecosystem, enabling secure health records, improved care coordination, and population-scale data infrastructure that supports research, real-world evidence, and precision health.

For multinational companies, this digital backbone creates a uniquely strategic environment, enabling large-scale clinical research, faster pharmacovigilance, AI-supported health insights, and rapid deployment of innovation across diverse populations. India’s digital infrastructure is not simply modernizing health delivery. It is enabling national-scale transformation.

BIOAsia sits at the center of this conversation and convergence. The gathering reflects India’s ambition to lead at the intersection of biology, artificial intelligence, and scalable innovation. Leaders from industry, government, and science convene not only to discuss growth but to shape the next phase of global life sciences, where biology, data, and digital systems converge to influence global health.

One conference panel, among the many high-powered sessions, brings together global leaders in advanced therapeutics to explore how next-generation modalities are moving from discovery to scalable care. Panelists across biopharma, translational science, and hospital systems are examining progress in cell and gene therapies, mRNA, and radiopharmaceuticals, underscoring that innovation now depends as much on manufacturable scale and delivery as on scientific breakthrough. India’s expanding capabilities in clinical research and bioprocessing strengthen its role as a key partner in advancing next-generation therapies.

For multinational innovators, the implications are clear. Engagement in India now extends beyond commercialization. It calls for collaboration in research, investment in digital and scientific ecosystems, alignment with national health priorities and partnership in strengthening health delivery.

India’s Strategic Role in Global Health Innovation

India’s rise in global health innovation reflects the alignment of policy, market growth, digital infrastructure, and scientific capability forces that together are reshaping where and how healthcare innovation occurs.

For multinational companies, India now represents a full-spectrum innovation environment. It is a place to conduct clinical research across diverse populations, scale manufacturing and supply chains, deploy digital health at a national scale, and co-develop solutions addressing both local and global health challenges. Increasingly, India is not simply a recipient of innovation developed elsewhere. It is becoming a co-creator of next-generation health.

This shift changes the strategic equation. Market entry alone is no longer sufficient. Meaningful engagement requires partnership with policymakers, regulators, scientists, health providers, and digital health ecosystems. Organizations that invest in collaboration, align with national health priorities, and contribute to strengthening healthcare systems are most likely to succeed in India’s evolving landscape.

BIOAsia sets the stage for this transformation. It is more than a conference. It is a convergence of global health ambition, scientific capability, and policy momentum. The conversations taking place in Hyderabad mirror a broader reality: the geography of health innovation is expanding, and India is now central to its future.

For global health innovators, the question is no longer whether India matters. The question is how deeply they choose to engage in shaping what comes next.

The post India: The Growing Focal Point for Health Innovation appeared first on Medika Life.

The health system in India will undergo a seismic shift due to the recent GST reforms. A sector that will see a significant impact is medical tourism, a crucial component of this sector. Unlike the past, when only a select few could afford to travel to other countries for medical treatment, the trend is changing today. According to the Medical Tourism Index, India ranks 10^th among the most sought-after destinations for medical treatment.[1]

The medical tourism sector in India is valued at $8.71 billion and is projected to reach nearly $16 billion by 2030, with a compound annual growth rate of 13.23%.[2] In 2023 alone, 635,000 foreign nationals came to the country seeking medical care.[3] While cost remains a massive draw, the true revolution lies in the holistic and value-driven ecosystem that the country has built. The country is not just offering an affordable alternative. It is redefining what “care beyond borders” means.

Why India is a popular destination

The country’s rise to becoming a global healthcare hub is due to several factors, such as:

• Cutting-edge facilities: There are several outdated notions regarding infrastructure and expertise in healthcare facilities in developing countries. India is proving these assumptions wrong. The country is home to a rapidly growing number of hospitals with state-of-the-art infrastructure, on par with some in the West. Healthcare facilities in several cities, including Delhi, Mumbai, Chennai, and Bengaluru, are equipped with cutting-edge technology and offer a comprehensive range of treatments in several areas such as cardiology, oncology, neurology, fertility treatments, and cosmetic surgery. Many of these institutions have received globally recognized accreditations from the Joint Commission International (JCI)[4] and the National Accreditation Board for Hospitals & Healthcare Providers (NABH), which serve as benchmarks of quality and safety.
• World-class expertise: At the heart of this transformation is the country’s intellectual capital. India has a vast pool of highly skilled medical professionals, many of whom have trained or practiced in prestigious institutions abroad. This creates a unique blend of international expertise with a deeply ingrained ethos of empathetic care.
• Favourable policies: The government has taken a keen interest in medical tourism and has created favourable schemes and initiatives. Some of these include the National Strategy and Roadmap for Medical and Wellness Tourism, a Medical and Wellness Tourism Board, overseas marketing, and e-medical visas. Similarly, the Heal in India initiative aims to highlight both modern and ancient healthcare on a digital platform, offering comprehensive support to those seeking care. Such positive steps have made it easier for medical tourists to access healthcare in the country.  
• Holistic care: Medical tourism is not limited to modern medicine. Tourists flock to the country every year to try out traditional healing systems such as Ayurveda and Yoga. This unique approach to wellness offers a comprehensive path to recovery, addressing the physical ailment and the patient’s mental and spiritual well-being.
• More than affordable care: Cost is an important aspect that draws scores of people, but India’s healthcare system is more than a medical bill. It includes a seamless patient experience, often managed by dedicated “medical value travel facilitators.” These services handle everything from visa assistance and travel arrangements to language interpretation and post-operative follow-up. Minimal waiting time is another critical factor, which can be a life-saving advantage in time-sensitive cases.
• Overcoming language barriers: An overlooked but practical advantage in India is the widespread use of English. Most doctors, nurses, and hospital staffers in major medical institutions speak in English, which makes communication easy and builds trust with international patients. This ease of interaction is a crucial factor when patients are making a decision about therapy, as it reduces anxiety and provides clarity about the treatment plan.

Navigating challenges and leveraging opportunities

Despite its position, the medical tourism sector faces several challenges. While government initiatives are yielding results, some systemic issues still need to be addressed. Simplifying the visa process, ensuring consistent quality across all tiers of hospitals, and building a stronger regulatory framework to protect patients are all vital steps for sustained growth.

At the same time, there are immense opportunities for growth. The rise in digital healthcare tools, such as telemedicine, is making cross-border consultations and follow-ups easier, bridging the geographical gap and building trust even before a patient leaves their home. The country’s strategic focus on attracting patients from a wider range of countries, which includes developed nations, by highlighting its comprehensive care model, will be key to helping this sector flourish.

Medical Tourism 2.0 may seem like a market trend, but it is redefining what healthcare can be. India, with its high-tech hospitals, skilled professionals, and a rich legacy of holistic wellness, is no longer a mere participant in this market. It is a catalyst for systemic change. The country’s commitment to patient-centric care is creating a model where healing is no longer limited by geography. The country is confidently positioning itself as a destination for treatment and a sanctuary for healing, proving that in the future, “care beyond borders” will be the new global standard.

[1] https://www.medicaltourism.com/destinations/india

[2] https://www.mordorintelligence.com/industry-reports/india-medical-tourism-market

[3] https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2036816

[4] https://www.jointcommission.org/en/about-us/recognizing-excellence/find-accredited-international-organizations?rfkid_7:content_filters=country:eq:India&rfkid_7:content_page=1&rfkid_7:content_limit=100

The post Care Beyond Borders: India Redefining the Future of Medical Tourism appeared first on Medika Life.

Perhaps the biggest wild card is Donald J. Trump’s return to the White House and the nomination of several candidates who have suggested that they will reinvent Health and Human Services, the Food and Drug Administration, Centers for Disease Control, and the Centers for Medicare and Medicaid Services—key agencies that set the agenda for public health and innovation.

The second unknown is the thin line separating misinformation from disinformation.  Historically, we looked to public health scientists to guide us.  Now, we are uncertain who to trust regarding health information.  Advice:  Do not rely on “X” as a fact-checking source – it’s merely noise.  But can you trust significant news sources, C-Suite execs, or elected officials?  It’s hard to say.  There is a vast divide between an honest mistake and willful deception. When it comes to health, do your homework – always!

A third factor must be included in the many 2024 health rankings and “Top 10” analyses that will appear in the days ahead. Our planet’s and people’s health are deeply intertwined. Rising temperatures, air pollution, and extreme weather events are not just environmental concerns but public health emergencies. These factors disproportionately impact vulnerable populations, exacerbating chronic conditions like asthma, cardiovascular disease, and mental health disorders. Addressing these challenges requires health professionals to embrace a broader perspective, recognizing that the fight for cleaner air, sustainable food systems, and resilient communities is inseparable from the mission to improve individual health outcomes.

Here are 10 health-sector developments—not ranked—to watch in the coming year, determined by media coverage, reader interest, and personal interest. These “10” could be Top Hundreds or Thousands. Happily, there were many advancements in 2024 to applaud. Yet, the pain points, too, are many. There are many publication lists to check – reviewing many is worthwhile. What is most important is to reflect on the needs of people and planet and commit to make a difference. The planet doesn’t need people. People need the planet. Equally so, people need each other.

This list’s topics were selected using data from global news outlets, academic publications, press releases, analytics platforms like Google Trends, and social media engagement metrics. While the list reflects the broad measure of public interest, it provides an overview of some of the positive and most worrisome health shifts and signals of what lies ahead.

1. AI-Powered Diagnostics Revolutionize Early Detection

Augmented implementation (AKA artificial intelligence) will redefine diagnostics in the years ahead. AI is poised to redefine diagnostics, with breakthroughs in the early detection of diseases like pancreatic cancer offering unprecedented accuracy and saving lives. Recent breakthroughs set the stage for broader adoption of AI in detecting other cancers and chronic diseases in 2025 and beyond, enticing the biopharma sector to interest in clinical trials to develop treatments for these deadly cancers.  This is a prime example of where AI can become a tipping point for earlier interventions and better patient outcomes globally.

2. India Leadership in Affordable Vaccine Development

India is quietly solidifying a reputation as the “pharmacy of the world” through several initiatives, such as launching a low-cost universal flu vaccine. Developed through a groundbreaking public-private partnership, this vaccine leverages advanced mRNA technology to provide broad-spectrum protection against multiple flu strains. By prioritizing affordability and accessibility, the initiative aims to protect millions of people in low- and middle-income countries, showcasing a scalable model for addressing global health inequities.

India has all the pieces to become a more significant player in the life science innovation puzzle – talent, scientific rigor, and an open-minded government willing to align its drug regulatory system with the world’s gold standard – the Food and Drug Administration.

India’s new rare disease center in New Delhi addresses critical global health gaps, setting a precedent for similar initiatives worldwide. Keep an eye on future developments from India to the world and investments from US-based life science companies in India’s strong talent base.

3. Breakthroughs in Alzheimer’s Disease Treatment

A novel gene-editing therapy targeting the APOE4 gene variant in the United States shows promise in addressing Alzheimer’s progression, and three new drugs were approved in the United Kingdom that may slow down memory decline in early Alzheimer’s disease. This continuing commitment by life science companies to invest in Alzheimer’s treatments after waves of disappointments could mark a turning point in one of the most vexing and worrisome neurodegenerative diseases.

Additionally, long-standing preventive disease pioneer Dean Ornish, MD, Founder and President of the Preventative Medicine Research Institute, has shown a possible pathway to reversing Alzheimer’s symptoms without medication. Ornish’s research on lifestyle interventions—emphasizing diet, exercise, and stress management—gained significant attention in 2024 and highlights the role of holistic approaches in improving cognitive health. His pathway does not dismiss using prescription medicine. Leading medical minds and consumers’ minds should take lifestyle medicine seriously.  It’s not the first time that Dr. Ornish has been proven right.

4. United Kingdom Moves Toward Digital Health Leadership

The United Kingdom launched a nationwide digital health initiative integrating wearable technology with its revered National Health Service (NHS). By enabling people to track chronic conditions like diabetes and hypertension in real-time, the initiative enhances patient engagement and accelerates preventive care delivery. Early results indicate improved patient outcomes and reduced hospital admissions. Looking ahead, 2025 could see the expansion of this initiative to include predictive analytics, further enhancing preventative care and patient empowerment.

UK Finance Minister/Chancellor Rachel Reeves announced in 2024 that the government is increasing the national health budget by US$29.33bn, a significant increase in NHS resourcing. Increased investment in infrastructure, technology and patient care position the United Kingdom as a launching point for new biomedical research and innovation waves.

5. Cancer Vaccines Gain Momentum

Personalized cancer vaccines emerged as a game-changing innovation in oncology. These vaccines train the immune system to target and destroy cancer cells based on the unique genetic mutations in an individual’s tumor, offering a highly tailored approach to treatment. A U.S.-based biotech company reported successful Phase 3 trial results for a melanoma vaccine, demonstrating significant reductions in recurrence rates.  

One promising example is the Moderna and Merck mRNA-based vaccine program for adjuvant treatment of high-risk melanoma. In Phase IIb results, the therapy showed a 44 percent lower risk of cancer recurrence or death compared to Merck blockbuster cancer drug Keytruda alone. Ongoing trials are exploring its efficacy in combating other cancers, such as lung and breast cancer. These are rigorous clinical programs with all the scientific peer-review requirements of a new medication.

6. America Begins to Take Serious Note of Obesity

The United States has finally begun to address obesity as a serious health concern. New policies and initiatives have been implemented to combat this epidemic, including improved access to nutrition education, increased funding for obesity research, and the development of innovative treatment options. Food and Drug Administration approval of new weight-loss GLP-1 drugs has sparked hope for more effective interventions. Additionally, public health campaigns have raised awareness about the long-term health risks associated with obesity, leading to a shift in societal attitudes and increased support for those struggling with weight management.

While weight-loss drugs offer promise, addressing obesity as a multifaceted health issue—spanning diabetes, heart disease, and more—remains critical. However, medications alone are not the miracle solution to the world’s weight problem. Will 2025 become the year of recognizing obesity as an umbrella disease?

7. Israeli Innovation –  Resilience Under Pressure

Sudden attacks from all directions would consume any nation’s emotional and physical energies. If so, the past 16 months should absolutely distract Israel – a country the size of New Jersey – and its nine million Jewish, Muslim, and Druze citizens – from anything other than self-defense.  Despite incredible challenges, Israel continues to innovate, with its 1,600 life science companies driving advancements in digital health, diagnostics, and bio-convergence. Israeli startups raised $2.43 billion in the third quarter of 2024 across 99 rounds, representing a 32 percent increase compared to the same period in 2023 (pre-October 2023)

The number of groundbreaking Israeli-developed medical devices, biologics, and information technologies incorporated into US-headquartered life science companies’ pipelines and product portfolios secures this nation’s position as a global innovator hub. Its role model hospital, Sheba Medical Center, ranks among the world’s top health systems and seamlessly integrates the country’s cutting-edge technologies in intensive care, telemedicine, early diagnostics, smart surgical equipment, and digital imaging throughout its system.

Israel is taking another leap in health innovation through its investment in bio-convergence. It is poised to play a significant role in the next technological wave of the 21st century. 

8. US Advances in Regenerative Medicine

Regenerative medicine focuses on repairing or replacing damaged tissues and organs, tapping into the body’s natural healing processes. Innovations like stem cell regeneration, cell therapy, diabetes and regenerative knee treatments offer alternatives to invasive surgeries and improve outcomes for chronic conditions.

Regulatory frameworks are crucial to this progress, providing clear guidelines and streamlined approval processes to ensure safety while fostering innovation. As regenerative medicine reshapes health delivery, it stands out as a transformative force in addressing some of the most pressing medical challenges. It is science fiction in many ways—maintain an open mind.

9. Global Antimicrobial Resistance Collaboration

The WHO’s global antimicrobial resistance network is a critical step in combating superbugs. It enables real-time data sharing to identify resistance patterns and drive new antibiotic development. It is a big deal. In a world where pathogens know no borders, collective action through such a network is essential to safeguarding the efficacy of treatments and protecting lives worldwide. The urgency has willing partners ready to engage.

This collaborative surveillance network is a big step forward in the response to a silent pandemic threatening global health. Coordinated action across nations equips health systems with real-time tools to identify and respond to resistance patterns. The rise of drug-resistant infections undermines decades of medical progress, turning treatable conditions into life-threatening challenges. A unified surveillance network enhances early detection and targeted interventions and drives the development of new antibiotics and stewardship programs.  Watch what happens in the coming year – our well-being is at stake.

10. A New White House Administration – Anxiety Versus Reality

As the second Trump administration prepares to take up residence in the White House, health ecosystem stakeholders are abuzz about potential policy shifts. Drawing from past actions and election campaign rhetoric, it’s anticipated that this administration – based on executive nominees such as Robert F. Kennedy, Jr., might implement changes through executive authority, bypassing congressional approval.  Food regulation policy is almost a given.  What about access to (some) vaccines? How about the review and regulations of medicines?  Verbal controversy leaves many wondering what will happen next.

The incoming administration’s health policy agenda remains uncertain, with potential changes to the ACA, Medicaid, and reproductive health policies sparking debate. Additionally, there may be moves to restrict access to abortion and contraception, reshape Medicaid through waivers and work requirements, and revise policies affecting LGBTQ+ health and immigration-related health needs.  The possibilities that can generate anxiety are numerous.  Wait and watch!

The Year Ahead and Beyond

These 10 health developments reflect the intersection of innovation, policy, and global collaboration. As we navigate 2025, the focus on improving lives and addressing disparities remains our collective responsibility – to rally to ideas and innovations that can improve people’s and our planet’s well-being.

From AI-supported diagnosis to vaccine breakthroughs in India and digital health leadership in the UK, the global health community demonstrates endless ingenuity. The developments of 2024 offer a roadmap for the future, proving that innovation is a team sport and together can overcome even the most formidable health challenges.

But innovation is like a Jenga structure—pull out the wrong piece at the wrong time, and health innovation can crumble or come to a screeching halt. It rests on three pillars: 1. People, 2. Policy, and 3. Investment. If policies do not support continued biomedical advances, equity and big business will likely search for other sectors that offer promise with a clear vision of a return on investment.

Let’s watch and advocate for a world where health in developed and emerging nations remains a top priority.

The post 2024 Health Trends: Progress, Challenges, and Opportunities appeared first on Medika Life.

A Changing Landscape: Opportunities in U.S.-India Health Ties

India’s rapidly evolving health sector and the U.S.’s unparalleled expertise in innovation and investment create a powerful synergy. India, already a global leader in pharmaceuticals, supplies 40% of generics to the U.S. and has emerged as a hub for cutting-edge manufacturing and research. Meanwhile, U.S. companies view India as a gateway to growth, with its burgeoning middle class, aging population of over 100 million, and a health market projected to reach $638 billion by 2025, growing at a 22% compound annual growth rate. The results of U.S. elections will directly influence health policies, including tariffs, trade agreements, and investment incentives, shaping the pace of collaboration between the two nations. Multinationals must navigate these shifts carefully, balancing policy changes with market potential.

Emerging Trends in the US-India Health Partnership

Reshaping the Pharmaceutical Supply Chain: With the U.S. increasing tariffs on Chinese imports and emphasizing domestic resilience, India has an unprecedented opportunity to fill the gap. Proposed legislation like the U.S. BIOSECURE Act positions India as a vital partner in contract manufacturing and research, doubling opportunities for Indian CDMOs and CROs. 

Incentivizing Innovation and Local Production: India’s Production Linked Incentive (PLI) and Make in India initiatives are revolutionizing domestic manufacturing. These schemes offer MNCs financial incentives to produce locally, reducing costs and enhancing access. U.S. companies like Pfizer and GSK have already capitalized on India’s pro-business policies, paving the way for others to follow.

Digital Health Revolution: India’s National Digital Health Mission and growing investments in telemedicine present lucrative opportunities for U.S. firms. Collaborating with India’s thriving tech ecosystem could help MNCs expand their digital health solutions, from AI-driven diagnostics to telehealth platforms, addressing unmet needs in rural and underserved markets.

Medical Devices as the Next Frontier: India’s recent ₹500 crore initiative to strengthen its medical devices sector aligns with U.S. expertise in advanced technologies. Partnerships in this space could make India a global exporter of high-quality medical devices, with MNCs playing a pivotal role in innovation and scale.

Why India is Unmissable for Multinationals

India’s health sector is undergoing a profound transformation, bolstered by government-led reforms and a favorable FDI regime. The allowance of 100% foreign direct investment through automatic routes in health and related sectors has already attracted global giants. Regulatory relaxations, such as waiving clinical trial requirements for drugs approved in select countries, make India an even more attractive destination for innovation. Additionally, India’s ambitious BIO-Ride Scheme aims to bridge the gap between research and commercialization, enhancing the country’s reputation as a biomanufacturing powerhouse. These developments, coupled with the expanding talent pool, provide multinationals with access to skilled professionals and cutting-edge research.

While the U.S.-India health partnership offers immense promise, challenges such as regulatory hurdles, intellectual property concerns, and geopolitical shifts must be addressed. Multinationals must adopt a strategic approach to align their goals with India’s priorities, from affordability to local capacity building. The future of health lies in the strength of the U.S.-India relationship. Together, the two nations can drive transformative change, addressing global health challenges through innovation, policy alignment, and mutual investment. Multinationals that recognize and act on this potential will not only unlock significant growth but also play a defining role in shaping the health landscape for generations.

As the post-election dust settles, one thing is clear: the U.S.-India health partnership is not just a bilateral opportunity—it’s a global imperative.

The post US -India Health Partnerships: A Blueprint for Global Health Innovation appeared first on Medika Life.

This move benefits Indian patients and has the potential to reshape the global pharmaceutical landscape. With India’s new policy, many multinational biopharmaceutical companies will need to reflect on how India evolves into a priority market.  

Speaking on the decision, Dr. V.G. Somani, Drugs Controller General of India (DCGI), Central Drugs Standard Control Organization, stated, “This policy shift is designed to bring the best of global medical innovation to India more swiftly. By relying on the robust data from international trials, we can ensure that Indian patients benefit from these advancements without unnecessary delays.”

This is more than just a regulatory update for multinational biopharmaceutical companies—it’s a strategic inflection point. India has long been considered a market of interest due to its significant population, favorable policy environment, and emerging middle class. Now, it has signaled its readiness to engage with the global pharmaceutical ecosystem on a new level.

The shift opens up a new market for these pharma companies. It presents an opportunity, but more importantly, a responsibility to extend their voice in India, increasing corporate brand reputation, science communication, and patient advocacy. It’s a turning point that could redefine the global pharmaceutical landscape, underscoring the weight of their role in shaping the future of healthcare.

S. Rajan, Chief Communications, Corporate Affairs and CSR officer at Roche, is among the industry leaders who applauded the GoI news: “This circular is a welcome and much-needed move. The calling out of specific drug categories will help drive a uniform and consistent understanding and avoid any delays. It is important that this is implemented well. We are hopeful that access to the latest innovations will be expedited, addressing unmet healthcare needs and benefitting Indian patients.”

Eliminating the cost barrier of conducting local clinical trials indicates that the GoI is seeking to address a public health need.  One obstacle has been removed, though others remain. Global biopharma companies still face significant challenges operating in India, primarily due to price controls impacting innovative therapies. At this time, India’s government enforces price caps that too often make it financially unviable for multinational companies to launch new, innovative drugs in this market. But it’s not impossible!

This is a favorable move to bring innovative cancer therapies and treatments for rare diseases to people in India. This remains a market of incredible potential, and biopharma companies will need to continue advancing innovative therapies and supporting them with economic solutions to make the best medicines available to more people worldwide. In the meantime, an expansion strategy to India is a medical and communication priority.

Investing in Corporate Brand Reputation

With India becoming a priority market, global pharmaceutical companies must assess how to build relationships with India’s medical and patient advocacy communities.  This is more than relying on marketing muscle. It’s about establishing a reputation as a trusted partner in health innovation and delivery in fast-emerging nations. This could involve initiatives such as collaborating with local healthcare providers, supporting patient education programs, and participating in policy discussions on health innovation and delivery in India.

Even before the GoI decision, the Indian pharmaceutical market was expected to grow to US$130 billion by 2030, up from US$42 billion in 2021, making it one of the fastest-growing health markets in the world.  The decision to embrace other nations’ regulatory moves will likely dramatically accelerate that growth.

Patrizia Cavazzoni, MD, Center for Drug Evaluation and Research, at FDA, has long tracked GoI decisions: “India’s decision to align its drug approval processes with global standards is a significant step that will foster greater collaboration. It also highlights the need for pharmaceutical companies to engage more deeply with Indian stakeholders, ensuring their corporate presence is synonymous with trust and transparency.”

Like audiences everywhere, the Indian public is increasingly discerning the corporate behaviors of those they entrust with their health.  People with urgent health concerns are excited about this decision, which will speed up access to therapies.  Companies must recognize that investing in world-class science may not be enough in the post-COVID era to secure physician support and consumer confidence.  To facilitate market entry in India requires establishing corporate identities people can trust.

The Imperative for Science-Based Communication

Effective science communication will be paramount as these companies introduce their health innovations into India. The complexities of advanced medical treatments, particularly newly approved ones, require careful explanation to health providers and the public.

Transparent, accessible communication will help demystify these innovations, fostering greater acceptance and understanding.  This also calls on major hospital provider systems that served as drug trial sites for these regulatory-approved medicines to step forward and share clinical backgrounds and best practices in patient care.

According to published studies, 87% of Indian physicians are highly engaged in continuing medical education (CMEs) and are keen to stay updated with the latest advancements in treatments and drug safety protocols, highlighting a receptive audience for apparent, data-driven communication efforts. Companies have an opportunity to lead by example, demonstrating that they are bringing innovative products to market by showing commitment to educating and empowering Indian patients and health professionals.

Dr. V.G. Somani, DCGI, emphasized the importance of clear communication in this new regulatory landscape: “Pharmaceutical companies must now rise to the challenge of effectively communicating the science behind these treatments to healthcare providers and patients. This will be crucial in ensuring that the benefits of these new therapies are fully realized.”

Patient Advocacy as a Pillar of Reputation

Most crucially, multinational pharmaceutical companies must prioritize patient advocacy in India. The recent regulatory change will undoubtedly bring some innovative treatments to the market. The policy change is a catalyst toward ensuring treatments are accessible, affordable, and aligned with patients’ needs.  However, it remains a complex challenge.  India has 1.4 billion people – as many as 400 million classified as middle class – and a diverse and complex healthcare insurance system that includes government, private, and, in some cases, a heavy reliance on consumer out-of-pocket payments.

Companies must engage with patient communities, understand their unique challenges, and advocate for solutions that address them. Organizations such as the Organization for Rare Diseases India (ORDI) and the Lysosomal Storage Disorders Support Society (LSDSS) are among the advocacy groups advocating for patients with rare diseases in India. ORDI ensures early diagnosis, treatment, and support for individuals with rare diseases, while LSDSS focuses on increasing awareness and providing access to therapies for lysosomal storage disorders.

Dr. Manjit Singh, LSDSS Executive Committee President, commented on the significance of this regulatory change: “This policy decision is a critical step forward for patients with rare diseases in India. It will help bring much-needed therapies to the market faster. Still, it also places the onus on pharmaceutical companies to ensure these treatments are accessible and affordable for all patients.”

By engaging with these patient advocacy groups, pharmaceutical companies can help amplify patients’ voices, ensuring their needs are central in developing and distributing new treatments. Over time, this will include ensuring peer-reviewed science is shared with India-based media covering health and science, prioritizing pricing strategies to ensure accessibility to patient support programs, and investing in awareness efforts so that people with these conditions understand the importance of medication adherence.

The Government of India’s decision to waive local clinical trial requirements for drugs approved by gold-standard regulatory bodies is forward-thinking and aligns with the country’s demonstrated efforts to improve health delivery for serious illnesses. Multinational biopharmaceutical companies should get the signal that India is a welcoming market ready to be at the forefront of their phyician education and patient advocacy efforts. By investing in corporate brand awareness, scientific communication, and patient advocacy, these companies can contribute meaningfully to the health and well-being of India and other emerging nations. 

One barrier to access has been lowered for innovative cancer and rare disease therapies.  In reality, others remain.  One of the biggest is that the Indian National Pharmaceutical Pricing Authority sets ceiling prices – caps – that include certain patented and innovative drugs. The pricing formula often uses a cost-plus approach, a non-starter for significant biopharma companies championing breakthrough therapies in a price-referring policy environment.  But the door to possibilities has opened wider.

In responding to the GoI welcoming decision with action, the biopharmaceutical industry can reinforce its commitment to good business, science, and patient care—a true win-win-win for all involved and a global health impact. The message is clear: Pharma companies consider the possibilities and  “Go to India!”

The post India’s Pivotal Regulatory Shift: A Possible Game-Changer in Expediting Medicines to Millions in Dire Need appeared first on Medika Life.

Amidst this evolving demographic, the proliferation of smartphones, wearable health monitoring devices, telemedicine, and other health-tech applications driven by today’s digital age has transformed the way consumers engage with healthcare. This has given rise to an increasingly informed patient population who are constantly looking for ways to take their health into their own hands and on the alert for innovative self-management solutions.

Against this backdrop, we are seeing a steadily rising sector in the healthcare industry that has been gaining momentum – Consumer Healthcare (CHC).  Offering affordable and accessible options for preventive care and symptom management, the CHC sector is designed to provide easily accessible services for consumers such as over-the-counter medications, personal care items, and supplements. Having reached a value of USD 284.16 billion in 2022, the global CHC market is projected to soar to USD 608.39 billion by 2032, growing at a promising trajectory of 7.91% CAGR[3]. From a SEA context, CHC represents a captivating prospect for mitigating its demographic hurdles while unlocking growth opportunities for healthcare enterprises. Here’s how healthcare businesses can tap into this potential and leverage CHC to improve patient outcomes.  

The Perfect Storm: Challenges Driving CHC Demand in APAC

There are two key challenges creating a surge in CHC demand, with the first being growing non-communicable diseases (NCDs) in the region.

NCDs are a leading cause of mortality in SEA, responsible for approximately 62% of all deaths annually, and totalling around 9 million lives lost[4]. Alarmingly, half of these deaths occur among individuals aged 30 to 69 years, highlighting the significant impact on the productive age group[5]. Among NCDs, cardiovascular diseases (CVDs) claim the highest number of lives (3.9 million deaths), followed by cancers, chronic respiratory diseases, and diabetes.  Moreover, rapid urbanization has led to lifestyle changes characterized by sedentary behaviour, unhealthy diets, as well as increased tobacco and alcohol consumption. Traditional diets are being replaced by high-calorie, low-nutrient foods, contributing to obesity, hypertension, and diabetes. Additionally, despite efforts to curb tobacco consumption, smoking rates remain the highest (26.5%) in SEA[6]. Alcohol consumption is also increasing, particularly among young adults. Along with diagnosed cases, there is a substantial portion of the population living in rural areas of SEA with undiagnosed NCDs and who are unable to afford treatment. These factors point to a considerable unmet need for NCD-specific treatments and diagnostics to address the growing burden of these diseases in the region.

The burgeoning NCD burden in Southeast Asia highlights a critical need for accessible and affordable treatments and diagnostics. CHC products have the potential to fill this market gap, offering viable solutions to address the escalating prevalence of NCDs in the region.

Secondly, the heavy NCD burden is coupled with a critical shortage of trained healthcare professionals in the region, with insufficient doctors, nurses, and other medical personnel available to meet the healthcare needs of its population. For example, Indonesia faced a staggering deficit of 31,481 specialist doctors in 2023[7]. In the same year, the Philippines health department said that the country needed 125,890 nurses and 116,032 doctors to meet WHO standards, and it would take 25 years to close the doctor-patient demand gap[8]. As a result, patients may face long wait times for appointments, limited access to specialized care, and challenges in receiving timely medical attention. Furthermore, the shortage can lead to overburdened healthcare facilities, increased workloads for existing staff, and compromised quality of care as professionals feel burnout[9]. This exacerbates healthcare disparities and hampers efforts to ensure equitable access to healthcare.

Given SEA’s shortage of healthcare professionals, there is an urgent call for accessible and self-directed healthcare options. With the increasing demand for CHC products amidst these hurdles, the CHC sector offers a hopeful means to narrow the healthcare access divide and enable individuals to manage their health proactively.

Bridging the Gap: CHC’s Transformative Power

CHC also provides a wealth of benefits that cater to the region’s dynamic needs. One significant advantage of CHC is its appeal to the rising middle-class population in the Asia-Pacific region. By 2030, Asia Pacific’s (APAC) middle-class population is projected to grow from 1.38 billion in 2015 to 3.49 billion[10], indicating a surge in consumers with increased disposable income who prioritize personal well-being. In addition, 51% of APAC consumers are willing to pay more out of pocket for healthcare, while 50% of high-income groups are spending more on nutritional supplements[11]. This demographic shift underscores the growing demand for health-related products and services, positioning CHC as a key player in meeting evolving consumer needs.

Additionally, CHC products have the potential to overcome geographical barriers and reach underserved areas where traditional healthcare services are lacking. More than one-third – 1.6 billion – of the APAC population lack effective access to social health protection, and less than half of its workforce enjoys legal entitlement to income security in the face of illness[12]. Due to inadequate infrastructure, CHC can provide essential over-the-counter medications and healthcare essentials in remote and rural communities with limited access to clinics and hospitals. Within these communities, chain pharmacies, personal care stores, hospitals, and clinics can function as essential healthcare nodes, acting as the first point of contact for medical care and self-care. CHC products and OTC medicines, therefore, ensure that healthcare remains accessible to all.

Moreover, CHC can empower individuals to take control of their health through proactive self-care practices and readily accessible OTC solutions. By promoting preventive measures and offering easy access to healthcare products, CHC fosters a culture of health-consciousness and empowerment among consumers.

The Road Ahead: Collaboration and Strategic Partnerships

In charting the road into SEA’s CHC industry, collaboration amongst key stakeholders emerges as the cornerstone for advancing healthcare access and ensuring the seamless delivery of quality products and services to patients across the region. This includes strategic partnerships amongst healthcare providers, CHC companies, and governmental organisations.

For CHC companies looking to drive accessibility of their products, the relevant stakeholders must set up efficient distribution channels to ensure the seamless delivery of CHC solutions to underserved populations, particularly in remote and rural areas. CHC companies can do this by partnering with service providers who have a strong understanding of SEA’s market complexities, strong market expansion services, and an extensive delivery infrastructure catered to the region’s specific needs. For example, DKSH Healthcare’s capillary distribution network has a 90% penetration in CHC with over 100 years of experience in Asia, with strong reach into chain and independent pharmacies, convenience stores, supermarkets, and hypermarkets.

Additionally, navigating the intricate regulatory landscapes of SEA emerges as a pivotal challenge. Here, partnering with companies that boast extensive regulatory expertise becomes essential. Such partnerships facilitate the negotiation of diverse regulatory frameworks, ensuring compliance with stringent standards while expediting the introduction of CHC products to the market. DKSH Healthcare’s team of 90 healthcare experts provided end-to-end assistance on regulatory challenges to help businesses adhere to compliance standards, while ensuring that patient safety takes priority. Thus, collaborative efforts among stakeholders herald a promising trajectory for CHC in SEA, bolstering healthcare accessibility and efficacy across the region.

Towards a Consumer-Driven Future for Healthcare

As the region continues to navigate healthcare disparities and demographic shifts, the rise of CHC emerges as a transformative force in addressing pressing challenges. By empowering individuals to take charge of their well-being and bridging gaps in healthcare access, CHC also paves the way for a brighter, healthier future in Southeast Asia. With the support of collaborative initiatives, it’s time for CHC business and healthcare organizations to tap into CHC’s potential to revolutionize healthcare accessibility and efficacy across the region, paving the way for a consumer-driven future in healthcare.

[1] https://www.worldometers.info/world-population/south-eastern-asia-population/#:~:text=South%2DEastern%20Asia%20Population%20(LIVE)&text=The%20current%20population%20of%20South,the%20latest%20United%20Nations%20estimates.

[2] https://asia.nikkei.com/Spotlight/Datawatch/Aging-Southeast-Asia-grapples-with-weak-social-safety-nets#:~:text=In%202019%2C%20the%20ratio%20of,to%20the%20%22aged%22%20category.

[3] https://www.who.int/southeastasia/health-topics/noncommunicable-diseases#:~:text=Noncommunicable%20diseases%20(NCDs)%2C%20principally,accounting%20for%209%20million%20persons.

[4]  https://www.who.int/southeastasia/health-topics/noncommunicable-diseases#:~:text=Noncommunicable%20diseases%20(NCDs)%2C%20principally,accounting%20for%209%20million%20persons.

[5]  https://www.who.int/southeastasia/health-topics/noncommunicable-diseases#:~:text=Noncommunicable%20diseases%20(NCDs)%2C%20principally,accounting%20for%209%20million%20persons.

[6] https://www.who.int/news/item/16-01-2024-tobacco-use-declines-despite-tobacco-industry-efforts-to-jeopardize-progress

[7] https://www.integrity-indonesia.com/blog/2023/10/10/overcoming-medical-workforce-shortages-opportunities-and-challenges-for-foreign-doctors-in-indonesia/#:~:text=According%20to%20a%20report%20from,serving%20a%20population%20of%20277%2C432%2C360.

[8] https://www.philstar.com/headlines/2023/11/13/2311040/ideal-patient-doctor-ratio-seen-25-years-lawmaker

[9] https://www.bmj.com/content/382/bmj.p1655

[10] https://www.statista.com/statistics/255591/forecast-on-the-worldwide-middle-class-population-by-region/

[11] https://www.bain.com/about/media-center/press-releases/2024/asia-pacific-consumers-especially-gen-z-are-taking-greater-ownership-in-health-and-well-being-bain-survey-finds/

[12] https://www.ilo.org/asia/media-centre/news/WCMS_831314/lang–en/index.htm

The post The Rise of Consumer Health in Shaping Southeast Asia Treatment Accessibility   appeared first on Medika Life.

Our global leaders may regret not paying more attention to what is happening in health: in the geeky panels where I lurked, there was a conviction that health technology and artificial intelligence may help middle income countries to leap past their more fossilised advanced counterparts within a decade.

The oppressive silence

President Ursula von der Leyen of the European Commission set the tone in her opening remarks: democracy versus autocracy; the climate emergency and; helping global trade to recover and reorganise. She did mention health once, but only in the context of a pandemic that was now waning. And, President von der Leyen is a doctor by training, with a master’s degree in public health! The assorted foreign ministers and heads of development finance institutions did not, as far as I could tell, have a medical degree between them, so it’s maybe unsurprising that they glossed over the topic too. 

In fairness, Tadashi Maeda, the Governor of the Japan Bank for International Cooperation did talk about investment in Indian vaccine and small molecule production. I may have missed other contributions: each day began at 9am and ended 10.30pm; there were multiple breakout sessions twice a day and; all of the lunches and dinners were by invitation only. To no-one’s surprise, I was invited to the mealtime discussion on health issues around cooking oil rather than the exclusive meal hosted by the Indian foreign minister. 

Overall, though, I’m fairly sure that economy and finance leaders from across Africa, Asia, Europe and Latin America skipped any mention of the transformative approach to health that was the subject of so many promises from so many leaders throughout the pandemic. Geoffrey Onyeama the Minister of Foreign Affairs of Nigeria even managed about fifteen very eloquent minutes on the post-pandemic economic architecture without once touching on prevention, diagnosis or treatment of anything. 

Silence is sometimes welcome. In mediaeval Madrid or Rome, it must have been a relief not to be required to appease the Inquisition by applauding yet another lecture on how the sun revolved around the Earth; at Raisina, we were spared too many doctrinal lectures on the need for vaccine and medicines production in every back yard. At a meal in an outside restaurant, where each of us looked over our shoulder frequently to check that our heresy wasn’t being overheard, I spoke to a senior adviser to an African president who agreed that there was no sign anyone would pay a premium for products produced in Africa and that those products would inevitably be much more expensive than vaccines and medicines from highly efficient factories in India and in the advanced economies. Just look at South Africa’s Aspen, he said. 

Why it was better to be with the geeks

The Raisina organisers had made sure that, wherever the attention of the geopoliticians wandered, health would have protected sessions. The briefing book had a number of thought-provoking articles and I was lucky enough to be on the panel of a discussion about “Healthcare, Technology and a Coalition of the Willing” (warning: it’s an 85-minute video).  

The G20 will be chaired by emerging economies for the next three years (assuming a compromise can be found over Russia’s position in it). Indonesia’s turn is first. Dino Patti Djalal, the Chairman of Foreign Policy Community of Indonesia, and a former ambassador to the US, said that data and the rules governing access to it would be a focus of its presidency. In a world that has become used to COVID apps as a prerequisite to normal life, he saw vast opportunities for technology to transform healthcare delivery, but no guarantee that it would — more about this in a moment. Indonesia is also pushing for an “IMF of health” that would act as a shared funding pool for countries facing health crises and the G20 is establishing a continuing task force that brings together health and finance ministers. As workforces age, health becomes an ever more vital prerequisite to economic growth.

India, which takes over the G20 in 2023,  has committed massively to digitisation transforming health in a country that will very soon be the world’s most populous. At a Federation of Indian Chambers of Commerce meeting on a road map for universal health care earlier this year, experts defended plans to have many fewer beds per thousand of population than the global norm by saying that screening and remote management would mean that every bed would be used efficiently. It’s not a pipe dream: multiple emergency rooms in Gujarat are already managed by one specialist supervising local teams of doctors and nurses who act as arms and legs; across Bihar, one of India’s most deprived states, kiosks staffed by paramedics with very basic training link to a call centre staffed by GPs and specialists in Delhi who can send prescriptions, order diagnostic tests or refer the patient immediately.

Preeti Sudan, the Health Secretary who oversaw India’s initial forceful response to COVID, said that the country could not have managed the pandemic without AI predicting emerging hotspots. Nor could it have delivered 1.85 billion vaccine doses of COVID vaccines. 

India takes the potential of artificial intelligence in health so seriously that it has seconded a full ambassador to run I-DAIR, a Geneva-based international collaborative. In the future, massive databases are likely to be more prized assets than a collection of patents or closed collaborations with academic centres. Ambassador Amandeep Gill foresees an alliance of small states and large low and lower-middle income countries. The Switzerlands and Singapores will bring money and expertise; the populous countries will bring data and the chance to find patterns that will transform diagnosis treatment (and fast-emerging health tech hubs in countries such as India and Kenya).

Change, though, is frightening. In many situations, AI can already predict more accurately than humans which pathogen is likely to be responsible for a patient’s infection and can predict which antibiotics are likely to work against it. Why do you need a doctor? This kind of change will be even more profound in areas such as cancer and management of cardiovascular disease. Ss Ambassador Djalal said, “doctors are enormously egotistical, especially when it comes to their revenues”. We need, he said, to prepare for political and social resistance from those who’ve benefited from the current system. 

The last time I saw the figures, Indonesia had fewer than 200 medical oncologists for about 270 million people. If they are worried, imagine how the average American oncologist will feel: there are about 13,000 of them for a population that is only 20% bigger than Indonesia’s. They earn an average of $300,000 a year, according to Glassdoor. As South African minister Kwati Candith Mashego-Dlamini told the panel, health technology will allow South Africa to spread its few oncologists more thinly; that should be what worries the office-based oncologist in Topeka. No one is suggesting that there will be no role for oncologists or cardiologists in the future; just that their role will be different, and probably less well paying. 

The Americans and the Europeans are likely to resist for longer: there are more of them and they account for a much larger percentage of GDP than do their counterparts in middle income countries. Today, Indians can get some cardiovascular surgery with a better chance of survival and at prices as low as two percent of the cost of the procedure in the USA. This achievement was reported by INSEAD, Europe’s leading business school in 2012, but the Indian model has yet to be replicated in Europe or North America.  It is likely, then, that AI-driven healthcare will reach its full potential in India and Indonesia before it does in the United Kingdom or the United States. The advanced economies will probably be late adopters, not refusers, though.

Power will shift in medical research too. A New Scientist article explained it beautifully in 2019. “Because all humans originated in Africa, groups that later migrated elsewhere took only a fraction of genetic diversity with them. Two individuals within an African population will be much more different than two individuals within a European population…The higher level of genetic diversity within Africa gives researchers the opportunity to investigate whether particular gene variants are associated with particular diseases. “For example, if you had a gene that was not variable at all in Europeans, you could not find an association with disease,” says [a researcher].  If there was variability in the same gene in people of African descent, that could lead to the development of a drug that could be used globally.” 

In the new era, Europeans and North Americans will discover that their majority populations are genetically impoverished, while minorities at home and — even more so — people still living in Africa and South Asia hold the key to new medical interventions. Imagine an American HHS Secretary begging a Mozambican health minister for access to the country’s genetic databases. Those geopoliticians will regret missing our session!

The post Global Elite are Bored with Health, Just When It’s Getting Really Exciting appeared first on Medika Life.

Then, mid pandemic surge New Delhi announced an unexpected shift in its vaccination strategy. It’s a change that has left many concerned and with good reason. The announcement to expand the vaccination campaign to all adults below 45 starting next month is a late but welcome move. India now has a daily infection rate of almost 350,000 and daily deaths are headed northwards of 3000 a day. The issue India now faces is that New Delhi appears to be worming its way out of both responsibility and accountability for vaccination by shifting a big part of the financial burden to India’s 28 state governments.

What this means in effect is that new vaccines need to be purchased from manufacturers on a state-by-state basis, assuming all states have adequate funding to afford to vaccinate their populations. Many don’t. Additionally, letting private hospitals buy shots at 600 to 1200 rupees ($8 to $16) apiece — and sell them to patients at even higher prices is a recipe for profiteering and vaccine discrimination.

Narendra Modi’s government has essentially created the perfect environment for a vaccine bidding war between states. Limited supplies have to be sent somewhere and this choice may very well come down to wealthier states being able to outbid their poorer neighbors. Limiting vaccine choice to the two indigenous vaccines also means that it’s a closed and very protected market the manufacturers can exploit, rather than opening the option to states for purchasing alternate vaccines from other sources. 

India currently suffers the unfortunate consequence of an earlier Covid lockdown, 75 million newly impoverished people to add to the additional 60% of the population that lives below the poverty line, according to a 2020 article.

The World Bank classifies nations into four broad income categories on the basis of which they are assigned three poverty lines. The lower-middle-income category, in which India also falls, has countries where per-capita annual gross national income is between $1,026 and $3,995 (between Rs 78,438 and Rs 3 lakh). In these countries, those earning less than $3.2 a day (around Rs 78,000 per year) are considered to be below the poverty line.

To place that figure into context, that’s over 812 million — in addition to the 75 million mentioned above — people that cannot afford to pay for vaccination. It’s 812 million reasons to ensure that any vaccine discrimination or policies that encourage discrimination or profiteering are outlawed. It’s 812 million reasons to question Narendra Modi’s proposed changes to India’s vaccination strategy.

A political storm looms

Modi is currently facing rising and vocal criticism from across India. A number of factors and poorly thought-through policies have contributed to his current predicament.

• Emergency hospitals constructed in 2020 to deal with expected bed shortages for the first waves of Covid were disassembled this year, Modi confident that India had beaten the virus. The Sardar Vallabhbhai Patel Covid hospital in Delhi was first built in 2020 in a record time of 12 days by the DRDO after a spike in cases. The facility was dismantled in February this year after the number of cases came down. It has now been re-opened with reduced capacity, as similar facilities across the country are desperately being recommissioned. 
• The vast majority of the factories that produce oxygen in India are located in the eastern part of the country — more than a thousand miles from major cities like New Delhi and Mumbai. This has created major bottlenecks in transporting oxygen tanks, which cannot be flown. It has created a once in lifetime logistics nightmare that is costing people’s lives. Seven months ago, the country had grappled with a similar oxygen shortage amid a rapid surge in case numbers. But this time, it’s much worse and hard questions are being asked.
• India’s hospitals are substandard and lack of investment and development in healthcare has been highlighted by the harsh Covid surge, as patients die in taxis, ambulances, and on the streets outside hospitals, waiting in the desperate hopes of being admitted to buildings that are functioning at double their intended capacity. Many simply die at home, unable to secure oxygen, medication, or a bed and overcrowded facilities simply increase risk to both staff and patients.
• New Delhi has done little to regulate price gouging and a basic drug like the anti-viral, Remdesivir now retails for around 300% more than its list price on the black market.
• Despite the surge, rallies and local politics continue unabated. About 8.6 million voters were expected to cast ballots on Monday in the eastern state of West Bengal, in the final phases of a contest set to wrap up this week. Also voting in local elections was the most populous state of Uttar Pradesh, which has been reporting an average of 30,000 infections a day.

Modi’s new vaccine strategy entails the following. State governments and private hospitals can order up to 50% of the vaccine stock to inoculate the younger population (under 45), while New Delhi will provide for free the other half to complete vaccination of those over 45. Serum (AstraZeneca) has announced individual vaccine prices of 400 rupees for states, and 600 rupees for private hospitals. Bharat’s rates (Covaxin) are 600 and 1200 rupees, respectively. That’s a significant hike from the original price Modi had negotiated, of 150 rupees.

Worrying questions that must be asked

Does the original vaccine price negotiated by New Delhi still hold with manufacturers and if so, why are states not able to avail themselves of the same price.? Why are vaccine manufacturers engaging in price gouging with the states and who stands to profit from this?

Everyone is in agreement, except, apparently the architects of India’s new vaccination strategy. The only acceptable cost to India, one that would allow for vaccination to be effective and widespread, without discriminatory practices affecting delivery, would be 0 rupees per shot. Free vaccination, delivered in a way that cannot be influenced by price-fixing and queue jumping. Shifting onus onto states for providing the funding for all their citizens is both short-sighted and irresponsible.

It suggests that Modi may very well be playing politics with lives, seeking to shift the responsibility for the insanely complex task of vaccinating over a billion people elsewhere. If it goes wrong, which it is now almost guaranteed to, fingers will point elsewhere. They shouldn’t. The responsibility to ensure equitable and accessible vaccination for all rests squarely on the shoulder of the central government. On Modi’s shoulders and there can be no shirking this responsibility. 

India already suffers from global vaccine disparities and discrimination. World Health Organization director Tedros Adhanom Ghebreyesus wrote in a recent op-ed in The New York Times. 

“Yet of the more than 890 million vaccine doses that have been administered globally, more than 81 percent have been given in high- and upper-middle-income countries. Low-income countries have received just 0.3 percent.”

One Billion Vaccines

It’s an unimaginably daunting task, fraught with pitfalls, and only one clear course of action. For any vaccination campaign of this size to succeed and to ensure people are vaccinated within a period of time that allows for a meaningful impact on the current strains of the coronavirus, strong leadership stemming from a central point is required. Rather than engaging in multiple contractual arrangements for the purchase of a limited resource, the government should focus on a single supply point, namely itself.

Massive wealth inequality exposes more than half of India’s population to possible vaccine discrimination. It is the duty of a responsible government to ensure these individuals are not treated prejudiciously in the vaccination process. Speed is of the essence here and bidding wars will merely serve to slow the process. Allowing wealthy hospital chains to buy into vaccine stock will further prejudice poorer communities.

All in all, Modi may be well advised to seriously reconsider his new vaccination strategy. It smells a little fishy and it would appear to be designed to fail.

The post India Questions New Dehli’s Changes to National Vaccination Program appeared first on Medika Life.

Heel Inc. are unscrupulous and ruthless in their exploitation of gullible and desperate members of the public and people seeking real solutions for often terminal conditions. In the late ’80s, the U.S. Food and Drug Administration (FDA) concluded that Heel Inc. (then called BHI) was one of the most flagrant law violators among homeopathic marketers and they banned further imports of their products into the USA. You can read their full history in this very detailed post on their company and business practises.

 In 1997, the Albuquerque company was renamed Heel Inc, which now manufactures and distributes both BHI products and Heel products. Heel products are primarily marketed to practitioners, whereas BHI products are primarily marketed to consumers. The company also prints and produces possibly the most misleadingly titled publication in the history of health publishing, ‘ Journal of Biomedical Therapy’.

The company enjoys large sales in India, an area known for its fondness of alternate medicines and ‘cure-alls’. Heel’s most recent marketing success under their Dr Reckeweg brand (the companies founder) has been India’s embrace of one of their products for the treatment of Covid-19. The product is Dr. Reckeweg Arsenic Alb-30. So successful has their campaign been, that some Indian provinces have even approved its use.

The product is diluted arsenic, commonly used in homeopathic circles for the treatment of digestive disorders and other conditions. If you doubt the dangers of this product, read this clinical study on the effects of arsenic from homeopathic treatments. The image below is from a company that markets Heel Inc’s brand in India.

It may seem shocking to some people that Arsenic would be considered a treatment for Covid, but don’t forget that recently, and evidence suggests the practice continues, Americans were ingesting MMS (Bleach) for preventing Covid. Heel’s catalog of products is massive, over 1000 different lines, and their marketing is targetted, deceptive and highly effective. They have seen the space in the market provided by the homeopathic quacks and have moved in with the intent of dominating it.

Heel Inc. and the FDA

In January 2005, the FDA ordered Heel Inc. to stop making illegal claims for five products claimed to be effective in preventing or treating influenza. In 2010, the FDA and FTC jointly ordered Homeopathy for Health, of Moses Lake, Washington, to stop claiming that BHI Bronchitis, BHI Bronchitis for Children, BHI Flu Plus with Influenzinum, and Heel Gallium Heel were an effective anti-viral for respiratory flu, such as the then-current swine flu. The FDA also placed these products on its Fraudulent Products List.

Numerous prior actions, product import seizures and warnings were issued to Heel Inc. prior to this by the FDA, many of which can still be accessed online. In 2014, Heel announced that it would stop marketing within the United States and Canada after August 31, 2014. Its press release attributed the decision to two class-action suits that has caused a “substantial financial burden.” You can read the full details of these actions here.

In truth, Heel was bought out in 2014 by MediNatura Inc. (another US-based company), and the products were simply routed through this business. A visit to Medinatura’s web site shows three featured products on their front page, advertised as fighting, guess what? Cold and Flu symptoms.

Heel in Germany

You know you’ve been around awhile when the street your business is located in is named after the person who founded the company. Biologische Heilmittel Heel GmbH (Heel) is situated in Dr. Reckeweg-Straße in Baden-Baden. Its an institution in Germany and it speaks volumes to the marketing drive and market penetration of the company. The companies growth has also been ably abetted by Europe’s more lenient approach to homeopathy.

How does Heel feel about their products being marketed as Covid cures? They are delighted, I’m sure. Restricted by legislation in Europe and the USA with regards to claims they can make about the quackery they sell, India and Asian markets are ripe for exploitation. These markets are more loosely regulated, the customer is more susceptible to pseudoscience and less likely to sue if he meets an unfortunate end swallowing arsenic. What’s not to love?

If you can knowingly sell fake hope to terminal cancer patients and other seriously ill people, then a little cure for Covid isn’t even going to register on the ethics scale.

For those on the fence, there is absolutely no scientific proof of the value of homeopathic treatments and they most certainly cannot cure Covid or any of the other dizzying array of conditions claimed by their quack resellers. If you are ill, seek qualified medical advice from a certified medical doctor or healthcare provider.

The post Heel Inc. (Dr.Reckeweg): Homeopathy, Quacks and Covid Cures appeared first on Medika Life.